Browse studies

Find your next paid study

6 recruiting studies matching your filters

A Phase 3 Open-Label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment With a CDK4/6 Inhibitor

This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib +…

PIK3CA MutationHER2- Negative Breast CancerHormone Receptor Positive Tumor+3 more

Estimated

~$10 – $8,750

Relay Therapeutics, Inc.NCT06982521

Observational

A Phase 2 Study of TheraBionic P1 Device for Patients With Metastatic Hormone Positive Breast Cancer Post Endocrine Therapy

The goal of this clinical trial is to learn if the TheraBionic P1 device given to patients with advanced or metastatic HR positive, HER2 negative breast cancer…

HER2-negative Breast CancerHormone Receptor Positive TumorAdvanced Breast Cancer+1 more

Estimated

~$10 – $7,500

Barbara Ann Karmanos Cancer InstituteNCT07227831

Phase 1

A Phase 1/1b Open-Label, Multicenter, First-in-Human Study Evaluating Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of RGT-490 as a Single Agent in Adult Subjects With Locally Advanced or Metastatic PIK3CA-Mutated Solid Tumors Including HR+/HER2- Breast Cancers

This is a phase 1/1b, open-label, multicenter study consisting of sequential parts designed to evaluate the safety, tolerability, and effects pharmacokinetic (…

Breast CancerOvarian CancerEndometrial Cancer+6 more

Estimated

~$10 – $8,750

Regor Pharmaceuticals Inc.NCT07524322

Phase 2

I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)

The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which t…

Breast NeoplasmsBreast CancerBreast Tumors+8 more

Estimated

~$10 – $7,500

QuantumLeap Healthcare CollaborativeNCT01042379

Observational

A Window of Opportunity Pilot Study: TheraBionic P1 Device for Patients With Resectable Early-stage Breast Cancer in a Neoadjuvant Setting

The goal of this clinical trial is to learn if adding cancer-specific amplitude-modulated radiofrequency electromagnetic field therapy (TheraBionic P1 device) …

Breast Cancer Stage IBreast Cancer Stage IIBreast Cancer Stage IIIA+2 more

Estimated

~$10 – $7,500

Barbara Ann Karmanos Cancer InstituteNCT07218432

Phase 1

A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of INX-315 in Patients With Advanced Cancer

Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers. This…

Breast CancerBreast Cancer MetastaticHormone Receptor Positive Tumor+6 more

Estimated

~$10 – $8,750

Incyclix BioNCT05735080